Cyclophosphamide Pharmacogenomic Variation in Cancer Treatment and Its Effect on Bioactivation and Pharmacokinetics
Cyclophosphamide (Cy) is a prodrug that is mainly bioactivated by cytochrome P450 (CYP) 2B6 enzyme. Several other enzymes are also involved in its bioactivation and affect its kinetics. Previous studies have shown the effect of the enzymes’ genetic polymorphisms on Cy kinetics and its clinical outco...
Saved in:
Main Authors: | Ibrahim El-Serafi, Sinclair Steele |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2024-01-01
|
Series: | Advances in Pharmacological and Pharmaceutical Sciences |
Online Access: | http://dx.doi.org/10.1155/2024/4862706 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Optimization of antidepressant treatment by pharmacogenomics: a case report
by: Ying Zhang, et al.
Published: (2025-01-01) -
The promise and challenges of pharmacogenomics in psychiatry
by: Elaine Ah Gi Lo, et al.
Published: (2024-12-01) -
Cyclophosphamide: An Alternative Treatment in Crohn’s Disease
by: Gilles Lapointe, et al.
Published: (1989-01-01) -
Editorial: Insights in pharmacogenetics and pharmacogenomics: 2023
by: José A. G. Agúndez, et al.
Published: (2025-01-01) -
Biological Properties, Bioactive Constituents, and Pharmacokinetics of Some Capsicum spp. and Capsaicinoids
by: Gaber, El-Saber Batiha, et al.
Published: (2023)